The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Advancement Program, 2021SCARB2 as a Potential Target in Parkinson’s Disease
Study Rationale:
Mutations in GBA, a gene that encodes an enzyme called glucocerebrosidase, are a common risk factor for Parkinson’s disease (PD). Inside cells, glucocerebrosidase must be escorted to... -
Priority Biology, 2021Studying the Properties of Alpha-Synuclein Aggregates Amplified from Human Cerebrospinal Fluid
Study Rationale:
Aggregates of the protein alpha-synuclein, which accumulate in the brains of people with Parkinson’s disease (PD), can also be detected in biofluids like cerebrospinal fluid (CSF)... -
Research Grant, 2021Comparing the Effectiveness of Two Imaging Methods for Monitoring the Progression of Parkinson’s Disease
Study Rationale:
Parkinson’s disease robs the brain of dopamine, a neurochemical needed for normal movement and cognition. A variety of imaging methods can be used to monitor the brain’s dopamine... -
Therapeutic Pipeline Program, 2021Evaluation of a Drug that Removes Excess Iron from the Brain as a Treatment for Parkinson’s Disease
Study Rationale:
In Parkinson’s disease (PD), the death of cells in brain regions that control movement causes motor symptoms. Brain imaging studies show that iron builds up in these areas, damaging... -
Therapeutic Pipeline Program, 2021Novel Inhibitors of Cell Death for the Treatment of People with Parkinson’s Disease
Study Rationale:
Subcellular structures called mitochondria perform many critical activities for brain cells. They generate enormous amounts of energy and remove the calcium that floods into neurons... -
PIPETTE 4R Tau and Alpha-Synuclein PET Tracer Development, 2021San Antonio Ligand Consortium (SALC)
Study Rationale:
The development of alpha-synuclein and 4-repeat tau (4RT) positron-emission tomography (PET) imaging agents would benefit people with Parkinson’s disease (PD), progressive...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.